|
D.10.Concomitant medical products and therapy dates: eliquis 5 mg, asa 81 mg, colace 100 mg, jardiance 10 mg, metformin 750 mg.H.6.Investigation findings for analysis of production records: code c19 - the review of the manufacturing paperwork verified that the lots involved in this event met all pre-release specifications.H.6.Investigation conclusions: code d15 - there is insufficient information available for gore to reasonably draw conclusions related to aspects of the event, therefore conclusion code ¿d15: cause not established¿ is being used.Insufficient information may include limited or missing relevant medical records, involvement of multiple implanted devices (including non-gore devices) in the field of treatment, patient non-compliance, and/or a general lack of available detail or specificity related to an adverse event and/or device.According to the gore® excluder® aaa endoprosthesis instructions for use, potential device or procedure related adverse events that may occur and/or require intervention or additional intraoperative procedure time include, but are not limited to, endoleak.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
On (b)(6) 2024, the patient underwent endovascular treatment of a ruptured left common iliac artery aneurysm using gore® excluder® aaa endoprostheses.A plc271000 contralateral leg component was implanted in the patient's right common iliac artery.There were no reported issues with device placement and the procedure was successfully completed.On (b)(6) 2024, a distal type i endoleak was observed from the plc271000 in the patient's right common iliac artery.The patient was transferred to (b)(6) for reintervention.On (b)(6) 2024, a reintervention was performed by (b)(6).A gore® excluder® iliac branch component was implanted to treat the distal type i endoleak.The internal iliac artery was preserved and the endoleak was successfully treated.There were no patient adverse events during the reintervention, and the patient tolerated the procedure.
|